Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Monoclonal Antibodies' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Monoclonal Antibodies' found in 1 term [] and 3 definitions []
1 - 4 (of 4)     
Result Pages : [1]
Searchterm 'Monoclonal Antibodies' was also found in the following services: 
spacer
News  (1)  
 
Monoclonal AntibodiesInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
(McAb) Monoclonal antibodies are used for tumor detection and localization in nuclear medicine. In MRI, monoclonal antibodies labeled with paramagnetic or superparamagnetic particles are being studied for targeting tumors, for example contrast agent containing gadolinium attached to a targeting antibody. The antibody would bind to a specific target (e.g., a metastatic melanoma cell) while the gadolinium would increase the MRI signal. Further developments are MRI contrast agents that specifically target glucose receptors on tumor cells; coupled with the high spatial resolution of high field MRI devices, these agents have potentials to detect small tumor foci.
The monoclonal antibody manufacturers produce a wide variety of ligands, which can be directed against a multiplicity of pathologic molecular targets. MRI enhanced with targeted contrast agents can be used for molecular imaging.
spacer
 
• Share the entry 'Monoclonal Antibodies':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  News & More:
Measuring mAbs with magnetic resonance can help regulatory testing
Thursday, 23 April 2015   by www.biopharma-reporter.com    
Repligen - Eyeing Sustainable Profitability
Monday, 31 October 2011   by www.rttnews.com    
Searchterm 'Monoclonal Antibodies' was also found in the following service: 
spacer
Ultrasound  (1) Open this link in a new window
Cytogen CorporationMRI Resource Directory:
 - Manufacturers -
 
www.cytogen.com

[This entry is marked for removal.]

Cytogen Corporation of Princeton, NJ is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several products through its in- house oncology sales force: ProstaScint® (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed™ I-125 and BrachySeed™ Pd-103 (two uniquely designed, next generation radioactive seed implants for the treatment of localized prostate cancer), and NMP22® BladderChek™ (a highly accurate and convenient antibody-based point-of-care staging test for bladder cancer detection). Cytogen has also developed Quadramet®, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer. Cytogen's pipeline comprises product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA (prostate specific membrane antigen) technology, which was exclusively licensed from Memorial Sloan-Kettering Cancer Center.
A license and marketing agreement with AMAG Pharmaceuticals Inc' (formerly Advanced Magnetics), to market the functional molecular imaging agent Combidex®, was terminated in 2007.

Contact Information
MAIL Cytogen Corporation
600 College Road East, CN5308
Princeton, NJ 08540-5308
USA
PHONE +1-609-750-8201
FAX +1-609-750-8124
ONLINE www.cytogen.com


spacer

• View the DATABASE results for 'Cytogen Corporation' (2).Open this link in a new window


• View the NEWS results for 'Cytogen Corporation' (14).Open this link in a new window.
 
Further Reading:
  Basics:
Combidex®(.pdf)
2005   by www.fda.gov    
MRI Resources 
MRI Accidents - Calculation - Libraries - Online Books - Mass Spectrometry - Stent
 
Molecular Imaging
 
Molecular Imaging is a new diagnostic discipline to visualize biological processes.
Molecular magnetic resonance imaging (mMRI) offers the potential to image tissues at the cellular and subcellular level. Targeted MR contrast agents enhance the diagnostic specificity and range of molecular magnetic resonance imaging.
Other modalities that can be used for noninvasive molecular imaging:
Ultrasound;
optical imaging;
positron emission tomography (PET);
single photon emission computed tomography (SPECT).
See also Nanoparticle, Monocrystalline Iron Oxide Nanoparticle, Polycrystalline Iron Oxide Nanoparticles, Liposomes, Monoclonal Antibodies, Bimodal Imaging, Tumor Specific Agents, and Intracellular Contrast Agents.
spacer

• View the DATABASE results for 'Molecular Imaging' (10).Open this link in a new window


• View the NEWS results for 'Molecular Imaging' (28).Open this link in a new window.
 
Further Reading:
  Basics:
Multimodal Nanoparticles for Quantitative Imaging(.pdf)
Tuesday, 13 December 2011   by alexandria.tue.nl    
Molecular Magnetic Resonance Imaging(.pdf)
2005   by www.medical.siemens.com    
  News & More:
Smarter MRI diagnosis with nano MRI lamp
Monday, 6 February 2017   by www.eurekalert.org    
Molecular MRI technique gives early indication of cancer treatment effectiveness
Monday, 11 April 2016   by www.healthimaging.com    
Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Bjorn Wangler
Thursday, 4 February 2016   by www.news-medical.net    
Positron Emission Tomographic Imaging in Stroke
Monday, 28 December 2015   by www.ncbi.nlm.nih.gov    
Potential and Limitations of Oxygen-17 MR Perfusion Measurements
Monday, 1 March 2004   by www.case.edu    
Searchterm 'Monoclonal Antibodies' was also found in the following services: 
spacer
News  (1)  
 
Tumor Specific AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Tumor specific MRI contrast agents are in development to provide better delineation and progression information for various tumors. Clinical oncology has a need for contrast agents that can identify tumors and metastases at a size of 100,000 cells rather than 1,000,000,000 cells. This level of sensitivity requires excellent tumor targeting of imaging agents and a high MRI signal.
Tumor specific agents accumulate at pathological tissues by passive or active targeting mechanisms. Passive targeting agents use e.g., the natural defense mechanisms in which phagocytic cells remove foreign particles from the body. Active targeting is based on a ligand-directed, site-specific accumulation of contrast agents. The availability of macromolecular contrast agents such as feruglose and ultrasmall superparamagnetic iron oxide (USPIO), which permit the assessment of tissue permeability, may also improve the detection of tumor grade, tumor type, and response to drugs that target angiogenesis.
See also Monoclonal Antibodies, Metalloporphyrins, Nitroxides and Ferrioxamine.
spacer

• View the DATABASE results for 'Tumor Specific Agents' (6).Open this link in a new window

 
Further Reading:
  News & More:
Smart Drug Developed to Show, Treat Cancer
Sunday, 18 November 2007   by www.koreatimes.co.kr    
MIT: Remote-control nanoparticles deliver drugs directly into tumors
Friday, 16 November 2007   by www.eurekalert.org    
Searchterm 'Monoclonal Antibodies' was also found in the following service: 
spacer
Ultrasound  (1) Open this link in a new window
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



In 2020 your scanner will probably work with a field strength of :
lower 
1T 
1.5T 
2T 
3T 
7T 
higher 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 25 May 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]